Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) Director Richard A. Heyman sold 1,270 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $27.67, for a total transaction of $35,140.90. Following the transaction, the director now owns 124,490 shares in the company, valued at approximately $3,444,638.30. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Enliven Therapeutics Stock Performance
Shares of ELVN stock opened at $28.02 on Friday. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $28.62. The firm has a market capitalization of $1.32 billion, a PE ratio of -14.52 and a beta of 1.10. The stock’s 50-day simple moving average is $23.92 and its 200-day simple moving average is $22.57.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.17. Sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.
Hedge Funds Weigh In On Enliven Therapeutics
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a report on Tuesday, October 1st.
Get Our Latest Stock Analysis on ELVN
About Enliven Therapeutics
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Stories
- Five stocks we like better than Enliven Therapeutics
- What is the Euro STOXX 50 Index?
- Cathie Wood Cuts Robinhood Holdings—Follow Her Lead or Stay Put?
- How to Effectively Use the MarketBeat Ratings Screener
- Wave Life Sciences Rockets 70% on Historic RNA Editing Success
- Most active stocks: Dollar volume vs share volume
- UPS vs. FedEx: Which Stock Delivers Better Holiday Gains?
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.